NEMO ‑binding domain peptide ameliorates inflammatory bone destruction in a Staphylococcus aureus‑induced chronic osteomyelitis model.

NEMO‑binding domain peptide ameliorates inflammatory bone destruction in a Staphylococcus aureus‑induced chronic osteomyelitis model.
Mol Med Rep. 2019 Feb 20;:
Authors: Lan Y, Xie H, Shi Y, Jin Q, Zhang X, Wang Y, Xie Z
Abstract
Osteomyelitis, which is characterized by progressive inflammatory bone destruction and resorption, is a difficult‑to‑treat infection. Staphylococcus aureus (S. aureus) is one of the major causes of this disease. This pathogenic microorganism possesses several characteristics, which facilitate its involvement in the occurrence and progression of osteomyelitis. A cell‑permeable peptide inhibitor of the IκB kinase complex, the nuclear factor (NF)‑κB essential modulator‑binding domain (NBD) peptide, has been reported to block osteoclastogenesis and may be considered a potential strategy for preventing inflammatory bone resorption. However, it remains to be determined as to whether the NBD peptide can regulate inflammation and bone resorption in S. aureus‑induced osteomyelitis. In order to investigate the role of NBD in S. aureus‑induced osteomyelitis, the present study obtained the NBD peptide, and confirmed that it inhibited receptor activator of NF‑κB ligand‑induced osteoclastogenesis in vitro. Subsequently, a bone defect was generated and S. aureus was injected into the mandible of experimental animals, in order to establish an in vivo osteomyelitis model. The present study ...

Source: Molecular Medicine Reports - March 4, 2019 Category: Molecular Biology Tags: Mol Med Rep Source Type: research